Clinical trials: Neoplasms, Solid Tumor
Solid Tumor, Adult
A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors
BY101921 is a novel small molecule, being developed as a PARP7 inhibitor which acts on the PARP7 catalytic subunit, for the treatment of solid tumors.
- Trial name
- NCT06433726
- Testing
- BY101921 tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
Tumors
Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of volitinib administered to patients with locally advanced or metastatic solid tumors and determine MTD (Maximum Tolerated Dose)…
- Trial name
- HMPL-504 (NCT01985555)
- Testing
- Volitinib(HMPL-504)
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Hutchison Medipharma Limited
Tumor Lysis Syndrome, Cancer
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
This is a randomized, multi-center, open-label, parallel group study with three arms: Rasburicase alone Rasburicase followed by Allopurinol Allopurinol alone The primary objective is to compare the adequacy of control of plasma…
- Conditions
- Tumor Lysis Syndrome, Cancer, Hyperuricemia
- Trial name
- NCT00230178
- Testing
- Rasburicase (SR29142), Allopurinol
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Sanofi
Mesothelin-positive Advanced Refractory Solid Tumors
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of novel Mesothelin CAR-T in patients with Mesothelin-positive advanced refractory solid tumors.
- Trial name
- NCT05531708
- Testing
- Anti-mesothelin CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Sponsor
- Shanghai Pudong Hospital
Solid Tumors Refractory to Standard Therapy
Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors
The goal of this clinical trial is to learn if a combination of Palbociclib and Sunitinib is safe and effective in various solid tumors.
- Trial name
- COPS-01 (NCT06940349)
- Testing
- Palbociclib, Sunitinib
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rabin Medical Center
MSI-H or dMMR Advanced Solid Tumors
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
This study is designed to evaluate the efficacy and safety of Anlotinib combined with AK105 injection or AK105 monotherapy in subjects with MSI-H or dMMR advanced solid tumors.
- Trial name
- NCT04291248
- Testing
- AK105, Anlotinib
- Where
- 9 sites in China
- Volunteers
- 138 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
The study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor activity of CN202 in adult subjects with locally advanced or metastatic solid tumor or hematologic malignancies
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Hematologic Malignancies
- Trial name
- NCT05028478
- Testing
- CN202
- Volunteers
- 164 people
- Sponsor
- Curon Biopharmaceutical (Australia) Co Pty Ltd
Perinatal Solid Tumors of the Thoraco-abdomino-pelvic Region
Perinatal Thoraco-abdomino-pelvic Tumors Study
Congenital tumors are a rare diagnosis in the fetus and newborn. They differ from those of children and adults in terms of the nature, location and evolution of the tumor.
- Trial name
- CONTRAST (NCT06365268)
- Testing
- Collection of data from the patient's medical file
- Where
- 5 sites in France
- Volunteers
- 152 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cachexia; Cancer
Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101
The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients.
- Trial name
- NCT07168226
- Testing
- Active Comparator, ASCA101 24.32mg/kg, ASCA101 32.43mg/kg
- Where
- 6 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- MetaFines
Solid Tumors
A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors
This study is a open-label, single-arm clinical trial designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of the GK01 cell injection in combination with a PD-1 monoclonal antibody for the treatment…
- Trial name
- GK01IIT-TZ03 (NCT07407985)
- Testing
- GK01 combination with PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Neoplasms, Lung Neoplasms
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.
- Conditions
- Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT00976508
- Testing
- figitumumab, pegvisomant
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 24 people
- Sponsor
- Pfizer
Unspecified Adult Solid Tumor, Protocol Specific
Smokefree.Gov Website in Helping United States Federal Employees Quit Smoking
RATIONALE: Stop-smoking information on the smokefree.gov website may help people quit smoking and remain a nonsmoker. PURPOSE: This clinical trial is studying how well the smokefree.gov website works with an electronic bulletin…
- Trial name
- NCT00245076
- Testing
- smoking cessation intervention, internet-based intervention
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Cancers
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.
- Trial name
- NCT02042989
- Testing
- MLN9708, Vorinostat
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
- Trial name
- NCT05580991
- Testing
- CAN1012
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Canwell Biotech Limited
Advanced Solid Tumor
APL-102 Capsule in Patients With Advanced Solid Tumors
This study will evaluate the safety and tolerability of APL-102 Capsule and characterize the pharmacokinetic (PK) profile in advanced solid tumor patients.
- Trial name
- NCT05055518
- Testing
- APL-102 Capsules
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Apollomics Inc.
Advanced Solid Tumors
The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere
This is a randomized, open-label, two-period, crossover trial to evaluate the pharmacokinetic profiles of albumin-bound docetaxel for intravenous infusion and Taxotere in patients with advanced solid tumors.
- Trial name
- NCT04811118
- Testing
- Docetaxel for Injection (Albumin-bound), Taxotere
- Where
- China
- Volunteers
- 27 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Anxiety, Depression
Brief CBT for Anxiety and Advanced Cancer
RATIONALE: Providing cognitive-behavioral therapy (CBT) may reduce anxiety and improve quality of life of patients with advanced cancer.
- Conditions
- Anxiety, Depression, Unspecified Adult Solid Tumor, Protocol Specific, Cancer
- Trial name
- NCT00706290
- Testing
- Brief Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Massachusetts General Hospital
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of…
- Trial name
- NCT02122913
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Bayer
Solid Tumor
A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor. Epitinib has demonstrated strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR mutations in pre-clinical setting.
- Trial name
- NCT02590952
- Testing
- Epitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Hutchison Medipharma Limited
Solid Tumor, Adult
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
This is an open label Phase 1a/1b study in patients who have advanced solid cancer tumours. Patients will receive MTL-CEBPA (an experimental drug) in combination with pembrolizumab (a drug which has been given approval for use…
- Trial name
- TIMEPOINT (NCT04105335)
- Testing
- MTL-CEBPA, Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Mina Alpha Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.